The incidence of relapse after therapy was significantly lower than that before therapy ( 2.4 A + / - 1.6 vs. 3.4 A + / - 1.1 times/year , p < 0.05 ) , and the required daily dosage of PSL after therapy was lower than that before therapy ( 0.39 A + / - 0.26 vs. 0.47 A + / - 0.24 mg/kg/d ; not significant ) .
